

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please cancel claims 80, 85, 104, and 108 without prejudice or disclaimer.

Please substitute the following claims 75, 81, 103, and 125 for the pending claims 75, 103, and 125, respectively:

-
75. (Amended) A DNA molecule which encodes an RNA molecule comprising:
- (a) at least one *cis*-acting sequence element,
 - (b) a first open reading frame which encodes a non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase of alphaviral origin, and
 - (c) at least one second nucleotide sequence selected from the group consisting of:
 - (i) a second open reading frame encoding a protein, or portion thereof, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events;

B¹

(ii) a sequence complementary to all or part of the second open reading frame of (i); and

(iii) a sequence encoding an untranslated RNA molecule, or complement thereof;

wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase.

81. (Amended) The DNA molecule of claim 75, wherein the RNA-dependent RNA polymerase is derived from a Sindbis virus.

103. (Amended) A DNA vector system comprising one or more polynucleotides which encode RNA molecules, said RNA molecules comprising:

(a) at least one *cis*-acting sequence element,
(b) a first open reading frame having a nucleotide sequence encoding a non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase of alphaviral origin, and

(c) at least one second nucleotide sequence selected from the group consisting of:

(i) a second open reading frame encoding a protein, or portion thereof, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events;

(ii) a sequence complementary to all or part of the second open reading frame of (i); and

(iii) a sequence encoding an untranslated RNA molecule, or complement thereof;

wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase.

125. (Amended) A composition comprising one or more RNA molecules, said RNA molecules comprising:

(a) at least one *cis*-acting sequence element,

(b) a first open reading frame having a nucleotide sequence encoding a non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase of alphaviral origin, and

(c) at least one second nucleotide sequence selected from the group consisting of:

(i) a second open reading frame encoding a protein, or portion thereof, wherein said second open reading frame is in a translatable format after one or more RNA-dependent RNA replication events;

(ii) a sequence complementary to all or part of the second open reading frame of (i); and

(iii) a sequence encoding an untranslated RNA molecule, or complement thereof;

B⁴ control
wherein said second nucleotide sequence is operably linked to a promoter which is recognized by said non-cytopathic, temperature-sensitive RNA-dependent RNA polymerase.

Add new claims 126-136.

126. (New) The DNA molecule of claim 75, wherein the RNA-dependent RNA polymerase is derived from a Semliki Forest Virus.

127. (New) The DNA molecule of claim 75, wherein the RNA-dependent RNA polymerase is derived from an Aura virus.

B⁵
128. (New) The DNA molecule of claim 75, wherein the RNA-dependent RNA polymerase is derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

129. (New) The DNA vector system of claim 103, wherein the RNA-dependent RNA polymerase is derived from a Sindbis virus.

130. (New) The DNA vector system of claim 103, wherein the RNA-dependent RNA polymerase is derived from a Semliki Forest Virus.

131. (New) The DNA vector system of claim 103, wherein the RNA-dependent RNA polymerase is derived from an Aura virus.

B⁵ cont'd
132. (New) The DNA vector system of claim 103, wherein the RNA-dependent RNA polymerase is derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylogach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

133. (New) The RNA molecule of claim 125, wherein the RNA-dependent RNA polymerase is derived from a Sindbis virus.

134. (New) The RNA molecule of claim 125, wherein the RNA-dependent RNA polymerase is derived from a Semliki Forest Virus.

135. (New) The RNA molecule of claim 125, wherein the RNA-dependent RNA polymerase is derived from an Aura virus.

136. (New) The RNA molecule of claim 125, wherein the RNA-dependent RNA polymerase is derived from a virus selected from the group consisting of Bebaru virus, Cabassou virus, Chikungunya virus, Easter equine encephalomyelitis virus, Fort morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus, Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate virus, Trinita virus, Una virus, Western equine encephalomyelitis virus, Whataroa virus, Venezuelan equine encephalomyelitis virus (VEE), and Ross River virus.

B⁵ cont'd